OTCPK:IVRO

Stock Analysis Report

Executive Summary

InVitro International develops test kits for non-animal testing in the United States and internationally.

Snowflake

Fundamentals

Adequate balance sheet with weak fundamentals.

Risks

  • InVitro International has significant price volatility in the past 3 months.
  • InVitro International's last earnings update was 3902 days ago.
  • InVitro International is not covered by any analysts.

Share Price & News

How has InVitro International's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-13.0%

IVRO

0.7%

US Medical Equipment

-0.2%

US Market


1 Year Return

58.2%

IVRO

9.5%

US Medical Equipment

1.1%

US Market

IVRO outperformed the Medical Equipment industry which returned 9.9% over the past year.

IVRO outperformed the Market in United States of America which returned 1.6% over the past year.


Share holder returns

IVROIndustryMarket
7 Day-13.0%0.7%-0.2%
30 Day-5.1%0.1%2.5%
90 Day4.4%2.5%1.6%
1 Year58.2%58.2%10.4%9.5%3.4%1.1%
3 Year161.0%161.0%69.3%64.1%45.2%35.8%
5 Year190.0%190.0%138.0%110.9%62.6%44.8%

Price Volatility Vs. Market

How volatile is InVitro International's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is InVitro International undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether InVitro International is trading at an attractive price based on the cash flow it is expected to produce in the future. But as InVitro International has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Examine InVitro International's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through InVitro International regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is InVitro International expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as InVitro International has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has InVitro International performed over the past 5 years?

0.2%

Historical Healthcare annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, InVitro International has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

Financial Health

How is InVitro International's financial position?


In this section we usually analyse InVitro International's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. InVitro International has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of IVRO’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when InVitro International's financial data was last updated here.
  • Explore more healthy companies in the Healthcare industry.

Dividend

What is InVitro International's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate InVitro International's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate InVitro International's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as InVitro International has not reported any payouts.

Unable to verify if InVitro International's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as InVitro International has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of InVitro International's salary, the management and board of directors tenure and is there insider trading?

25.2yrs

Average board tenure


CEO

Rich Ulmer (76yo)

24.8yrs

Tenure

US$139,518

Compensation

Mr. W. Richard Ulmer, also known as Rich, has been Chief Executive Officer, President and Director of Invitro International since November 15, 1994. Mr. Ulmer started his career in the health care and phar ...


Board Age and Tenure

25.2yrs

Average Tenure

77yo

Average Age

The average tenure for the InVitro International board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

No 3 month open market individual insider trading information.


Management Team

  • Rich Ulmer (76yo)

    CEO, President & Director

    • Tenure: 24.8yrs
    • Compensation: US$139.52k
  • Dennis Chenoweth (74yo)

    Senior Vice President and Director

    • Tenure: 24.1yrs
    • Compensation: US$125.85k
  • William Curtis (78yo)

    Executive Officer

    • Tenure: 34yrs

Board Members

  • Irwin Gruverman (85yo)

    Chairman of the Board

    • Tenure: 26.4yrs
  • David Reed (86yo)

    Director

    • Tenure: 23.1yrs
  • Rich Ulmer (76yo)

    CEO, President & Director

    • Tenure: 24.8yrs
    • Compensation: US$139.52k
  • Dennis Chenoweth (74yo)

    Senior Vice President and Director

    • Tenure: 24.1yrs
    • Compensation: US$125.85k
  • William Curtis (78yo)

    Executive Officer

    • Tenure: 34yrs
  • Jeff Safchik (67yo)

    Director

    • Tenure: 25.5yrs

Company Information

InVitro International's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: InVitro International
  • Ticker: IVRO
  • Exchange: OTCPK
  • Founded: 1985
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$1.097m
  • Shares outstanding: 21.02m
  • Website: https://www.invitrointl.com

Location

  • InVitro International
  • 330 East Orangethorpe Avenue
  • Suite D
  • Placentia
  • California
  • 92870
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IVROOTCPK (Pink Sheets LLC)YesCommon StockUSUSDMay 1991

Biography

InVitro International develops test kits for non-animal testing in the United States and internationally. Its products include Irritection Assay System, an invitro test, which could be used to detect, rank ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/20 00:16
End of Day Share Price2019/09/18 00:00
Earnings2008/09/30
Annual Earnings2008/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.